Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2020 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
Pediatric AML: From Biology to Clinical Management.
de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. de Rooij JD, et al. J Clin Med. 2015 Jan 9;4(1):127-49. doi: 10.3390/jcm4010127. J Clin Med. 2015. PMID: 26237023 Free PMC article. Review.
Survival rates have increased over the past few decades to ~70%, due to improved supportive care, optimized risk stratification and intensified chemotherapy. In most children, AML presents as a de novo entity, but in a minority, it is a secondary malignancy. ...These effor …
Survival rates have increased over the past few decades to ~70%, due to improved supportive care, optimized risk stratification and intensif …
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson BC, Samis J, Izquierdo M, Titorenko K, Li S, Sosothikul D. Hijiya N, et al. Blood Adv. 2023 Dec 12;7(23):7279-7289. doi: 10.1182/bloodadvances.2023010122. Blood Adv. 2023. PMID: 37738125 Free PMC article.
The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase 2, open-label DIALOG study …
The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philad …
The Diverse Roles of FLOWERING LOCUS C in Annual and Perennial Brassicaceae Species.
Soppe WJJ, Viñegra de la Torre N, Albani MC. Soppe WJJ, et al. Front Plant Sci. 2021 Feb 15;12:627258. doi: 10.3389/fpls.2021.627258. eCollection 2021. Front Plant Sci. 2021. PMID: 33679840 Free PMC article. Review.
In the Brassicaceae, the MADS box transcription factor FLOWERING LOCUS C (FLC) is a major regulator of flowering in response to prolonged cold exposure, a process called vernalization. ...We suggest that these additional roles of PEP1 are facilitated by (1) the ability of …
In the Brassicaceae, the MADS box transcription factor FLOWERING LOCUS C (FLC) is a major regulator of flowering in response to prolo …
Genomic Analysis of European Drosophila melanogaster Populations Reveals Longitudinal Structure, Continent-Wide Selection, and Previously Unknown DNA Viruses.
Kapun M, Barrón MG, Staubach F, Obbard DJ, Wiberg RAW, Vieira J, Goubert C, Rota-Stabelli O, Kankare M, Bogaerts-Márquez M, Haudry A, Waidele L, Kozeretska I, Pasyukova EG, Loeschcke V, Pascual M, Vieira CP, Serga S, Montchamp-Moreau C, Abbott J, Gibert P, Porcelli D, Posnien N, Sánchez-Gracia A, Grath S, Sucena É, Bergland AO, Guerreiro MPG, Onder BS, Argyridou E, Guio L, Schou MF, Deplancke B, Vieira C, Ritchie MG, Zwaan BJ, Tauber E, Orengo DJ, Puerma E, Aguadé M, Schmidt P, Parsch J, Betancourt AJ, Flatt T, González J. Kapun M, et al. Mol Biol Evol. 2020 Sep 1;37(9):2661-2678. doi: 10.1093/molbev/msaa120. Mol Biol Evol. 2020. PMID: 32413142 Free PMC article.
Genetic variation is the fuel of evolution, with standing genetic variation especially important for short-term evolution and local adaptation. To date, studies of spatiotemporal patterns of genetic variation in natural populations have been challenging, as comprehensive s …
Genetic variation is the fuel of evolution, with standing genetic variation especially important for short-term evolution and local a …
Effectiveness of wearable devices as a support strategy for maintaining physical activity after a structured exercise intervention for employees with metabolic syndrome: a randomized controlled trial.
Bayerle P, Kerling A, Kück M, Rolff S, Boeck HT, Sundermeier T, Ensslen R, Tegtbur U, Lauenstein D, Böthig D, Bara C, Hanke A, Terkamp C, Haverich A, Stiesch M, de Zwaan M, Haufe S, Nachbar L. Bayerle P, et al. BMC Sports Sci Med Rehabil. 2022 Feb 10;14(1):24. doi: 10.1186/s13102-022-00409-1. BMC Sports Sci Med Rehabil. 2022. PMID: 35144658 Free PMC article.
RESULTS: The total physical activity (in MET*h/week) declined between visit 2 and visit 3 (subgroup A: V2: 48.0 33.6, V3: 37.1 23.0; subgroup B: V2: 52.6 35.7, V3: 43.8 40.7, subgroup C: V2: 51.5 29.7, V3: 36.9 22.8, for all p = 0.00) with no between-subgroup differences o …
RESULTS: The total physical activity (in MET*h/week) declined between visit 2 and visit 3 (subgroup A: V2: 48.0 33.6, V3: 37.1 23.0; subgrou …
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N, Boer JM, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman HA, van der Velden VHJ, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Zur Stadt U, Schmiegelow K, Moorman AV, Zwaan CM, den Boer ML. Michels N, et al. Lancet Haematol. 2021 Oct;8(10):e700-e710. doi: 10.1016/S2352-3026(21)00272-6. Lancet Haematol. 2021. PMID: 34560013 Free PMC article. Clinical Trial.
Two matched cohorts were formed: for MRD analyses and for long-term outcome analyses. For both cohorts, matching was based on induction regimen; for the long-term outcome cohort, matching also included MRD-guided treatment group. ...FUNDING: Stichting Kinder Oncolog …
Two matched cohorts were formed: for MRD analyses and for long-term outcome analyses. For both cohorts, matching was based on inducti …
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.
Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT. Gratwohl A, et al. Ann Hematol. 2016 May;95(6):967-72. doi: 10.1007/s00277-016-2638-6. Epub 2016 Mar 19. Ann Hematol. 2016. PMID: 26994010 Free article. Clinical Trial.
It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Socie …
It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this …